Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
The Lancet Regional Health. Europe
|
June 15, 2026
Upward Air Temperature Shifts and Acute Cardiovascular Events in Individuals with Atherosclerotic Cardiovascular Disease: A Time-Stratified Case-Crossover Study
Katharina Lechner, Siqi Zhang, Nils Krüger, et al.
Frontiers in Cardiovascular Medicine
|
April 19, 2024
Cardiometabolic and immune response to exercise training in patients with metabolic syndrome: retrospective analysis of two randomized clinical trials
Katharina Lechner, Sylvia Kia, Pia von Korn, et al.
Innere Medizin (Heidelberg, Germany)
|
October 10, 2024
[Cardiovascular prevention in Saxony-Anhalt : Necessity and new perspectives]
Patrick Müller, Maximilian Herzog, Yves Duderstadt, et al.
Translational Oncology
|
December 18, 2020
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
Florian Heil, Galina Babitzki, Alice Julien-Laferriere, et al.
Blood Cancer Journal
|
September 4, 2021
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Karthik Ramasamy, Ajay Nooka, Hang Quach, et al.
Blood Advances
|
September 28, 2021
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
Michael Dickinson, Javier Briones, Alex F Herrera, et al.
BMC Cancer
|
March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
Blood
|
August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
Johannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.
The Oncologist
|
March 13, 2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
The Lancet Regional Health. Europe
|
June 15, 2026
Upward Air Temperature Shifts and Acute Cardiovascular Events in Individuals with Atherosclerotic Cardiovascular Disease: A Time-Stratified Case-Crossover Study
Katharina Lechner, Siqi Zhang, Nils Krüger, et al.
Frontiers in Cardiovascular Medicine
|
April 19, 2024
Cardiometabolic and immune response to exercise training in patients with metabolic syndrome: retrospective analysis of two randomized clinical trials
Katharina Lechner, Sylvia Kia, Pia von Korn, et al.
Innere Medizin (Heidelberg, Germany)
|
October 10, 2024
[Cardiovascular prevention in Saxony-Anhalt : Necessity and new perspectives]
Patrick Müller, Maximilian Herzog, Yves Duderstadt, et al.
Translational Oncology
|
December 18, 2020
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
Florian Heil, Galina Babitzki, Alice Julien-Laferriere, et al.
Blood Cancer Journal
|
September 4, 2021
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Karthik Ramasamy, Ajay Nooka, Hang Quach, et al.
Blood Advances
|
September 28, 2021
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
Michael Dickinson, Javier Briones, Alex F Herrera, et al.
BMC Cancer
|
March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
Blood
|
August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
Johannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.
The Oncologist
|
March 13, 2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, et al.
Page
of 6